Skip to main content
Caplight Logo









PhageLab

PhageLab

Private
SantiagoHealthcare & Life Scienceshttps://phage-lab.com/

Last Round

Series A

Jan 23, 2024

Total Funding Raised

$44.5M

Company Overview

PhageLab is a biotechnology company that develops precision bacteriophage treatments to reduce the overuse of antibiotics and control bacteria in the livestock industry.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

bacteriophage solution for animal productionAI-powered microbial bioinformatics platformcustomized phage cocktail for livestockantibiotic alternative for livestockmultidrug-resistant bacteria controlSalmonella control in poultryE. coli control in swinebacteriophage therapy for animal healthlivestock pathogen diagnostic serviceprecision medicine for animal healthClostridium perfringens control in swineanimal health biotechnology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PhageLab Comparables

Compare PhageLab with similar companies based on industry and business-model similarity.

PhageLab comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sciphage
83%
Phagos
83%
Proteon Pharmaceuticals
82%

PhageLab Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 23, 2024
Series AMay 23, 2022

Key People

Founding team and executive leadership

Pablo Cifuentes Palma

Chief Operating Officer

Executive Team

PhageLab Investors

Notable investors and investment history

PhageLab investors
InvestorRounds
NazcaSeries A
Humboldt FundSeries A
Collaborative FundSeries A
WaterlemonSeries A
The Yield LabConvertible Debt
KaszekSeries A, Convertible Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 23, 2024

    Raised $11M with participation from Collaborative Fund and Nazca.

  • May 23, 2022

    $30M round led by Humboldt Fund and Kaszek.

PhageLab Filings

Explore SEC and related filing metadata, where available.

PhageLab filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about PhageLab's valuation, stock price, and market status.

Is PhageLab a public or private company?

PhageLab is a private company.

What is the current stock price of PhageLab?

PhageLab is a private company with no public stock price. No recent secondary market data is available.

How much is PhageLab worth (valuation)?

Valuation information for PhageLab is not publicly available.

Can I buy PhageLab stock?

PhageLab shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was PhageLab's last funding round?

PhageLab's most recent funding round was Series A on January 23, 2024.

Who are the main investors in PhageLab?

Key investors in PhageLab include Kaszek.

Will PhageLab IPO soon?

No public IPO plans have been announced for PhageLab.

How can I track PhageLab secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor PhageLab's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSantiago
Employee Range48
Year Founded2010
Last FundingJan 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?